These sequences are extremely prone to mutations and rank among the most functionally important regions in the entire human ...

Cirtuvivint is a selective pan-CLK, pan-DYRK inhibitor that modulates alternative RNA splicing, including transcripts involved in oncogenic pathways. Preclinical studies have shown that CLK/DYRK ...

Here are the top 5 ovarian cancer articles of 2025; stay up-to-date with all the ovarian cancer content from The American ...

A research group at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has identified a candidate ...

Genome rearrangements often result from non-allelic homologous recombination (NAHR) between repetitive DNA elements dispersed throughout the genome. Here we systematically analyze NAHR between Ty ...

DNA double-strand breaks impact genome stability by triggering many of the large-scale genome rearrangements associated with evolution and cancer. One of the first steps in repairing this damage is 5' ...

Long-term safety of belzutifan in von Hippel-Lindau syndrome: A single-center experience. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full ...

ODAC unanimously opposed Talzenna/Xtandi for non-HRR-mutant mCRPC due to increased toxicity and undefined efficacy in non-HRR-mutated patients. UGN-102 for recurrent NMIBC faced a narrow vote against ...

The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in patients with prostate cancer who do not carry HRR mutations. The FDA’s ...

This manuscript reports important data providing evidence that a 42 amino acid region of Rev7 is necessary and sufficient for interaction with the Rad50-Mre11-Xrs2 complex in budding yeast. The ...